Q1 2026 Management View James B. Frakes, CEO and CFO, stated the company advanced its lead oncology indication clinical program, delivered preclinical results supporting broader applications including ...

Key Takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report ...

In August 2025, Seagen announced a studies how well tucatinib works for solid tumors that make either more HER2 or a ...